The use of the calcineurin inhibitors cyclosporine and tacrolimus led to major advances in
the field of transplantation, with excellent short-term outcome. However, the chronic …

Ample attention has focused on cancer drug delivery via prodrug nanoparticles due to their
high drug loading property and comparatively lower side effects. In this study, we designed a …

Introduction: The mTOR (mechanistic target of rapamycin, formerly known as mammalian
target of rapamycin) kinase is centrally involved in the regulation of cell growth and …

Introduction: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and
everolimus are used not only as immunosuppressants after organ transplantation in …

Background: The calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, have had a
revolutionary effect on the overall success of renal transplantation through reduction in early …

Cyclosporine and tacrolimus reduce allograft rejection, improve allograft half-life and patient
survival. Ironically, the nephrotoxicity of these agents may adversely affect allograft survival …

Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits cell cycle
progression and has proven to be a potent immunosuppressive agent for use in solid organ …

In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …

Individuals with type 2 diabetes have an increased risk of atherosclerosis. One factor
underlying this is dyslipidemia, which in hyperinsulinemic subjects with early type 2 diabetes …

Two prospective, randomized studies evaluated everolimus 1.5 vs. 3 mg/day with steroids
and low-exposure cyclosporine (CsA)(C 2 monitoring) in de novo renal transplant patients …